Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT03941366
NA

Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

Sponsor: Henry Ford Health System

View on ClinicalTrials.gov

Summary

The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.

Official title: Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (5FU/Capecitabine)-Radio Therapy (CRT) With Transanal Local Excision for Complete Responders

Key Details

Gender

All

Age Range

18 Years - 95 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2016-02-26

Completion Date

2025-04-01

Last Updated

2026-07-23

Healthy Volunteers

No

Conditions

Interventions

PROCEDURE

Standard of care chemotherapy with the change for avoidance of extensive surgery

All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.

Locations (1)

Ascension St. John Hospital

Detroit, Michigan, United States